TA-HPV human papillomavirus vaccine: Phase IIa data; Phase II

XEN said that in a U.K. Phase IIa trail of TA-HPV, 8 of 18 patients (44%) had objective clinical responses at 6 months, as measured by a ?50% reduction of lesions and pathology. Four patients (22%) sh...